November 28, 2018 07:52 AM ESTUpdated 08:07 AM
Financing

Can a biotech uni­corn break in­to the record books with a $600M IPO? Stéphane Ban­cel has a for­tune rid­ing on the an­swer

John Carroll

Editor & Founder

Stéphane Ban­cel’s life is about to change dra­mat­i­cal­ly.

The Mod­er­na CEO and his crew have post­ed the de­tails on their shot at the biggest biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Strug­gling biotechs suc­cumb to icy mar­ket, as mon­ey dries up and clin­i­cal bets don’t pay off

Vig­il drug fails a Phase 2; Merus aims to raise $300M

In a first, Sarep­ta an­nounces plat­form tech­nol­o­gy des­ig­na­tion for gene ther­a­py vec­tor

Anap­tys­Bio de­scribes ‘JAK-like’ ef­fi­ca­cy for PD-1 drug in rheuma­toid arthri­tis

Phar­ma com­pa­nies rush in to buy what they hope will ri­val Keytru­da

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times